Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience.

Saved in:
Bibliographic Details
Title: Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience.
Authors: Hultcrantz M; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Derkach A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Hassoun H; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Korde N; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Maclachlan K; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Mailankody S; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Patel D; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Shah UA; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Tan CR; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Chung DJ; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Lahoud OB; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Landau HJ; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Scordo M; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Shah GL; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Nemirovsky D; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Firestone RS; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Akhlaghi T; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Shekarkhand T; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Giralt SA; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Lesokhin AM; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Usmani SZ; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Source: Blood neoplasia [Blood Neoplasia] 2025 Apr 16; Vol. 2 (3), pp. 100103. Date of Electronic Publication: 2025 Apr 16 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 9918841988906676 Publication Model: eCollection Cited Medium: Internet ISSN: 2950-3280 (Electronic) Linking ISSN: 29503280 NLM ISO Abbreviation: Blood Neoplasia Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2950-3280
DOI:10.1016/j.bneo.2025.100103